Dexmedetomidine, Magnesium Sulphate and Lidocaine for Cough Suppression After General Anesthesia (MgSO4/DEX)

Al-Azhar University

Status and phase: Begins enrollment this month; Phase 3

Conditions: Cough

Treatments: Drug: Magnesium sulfate; Drug: normal saline; Drug: Lidocaine; Drug: Dexmedetomidine

Study type: Interventional

Funder types: Other

Identifiers

NCT06979141

MD/AZ.AST./AIP029/7/240/2/2025

Details and patient eligibility

About

The aim of this prospective randomized controlled double-blinded study is to compare the efficacy of dexmedetomidine, MgSO4 and lidocaine for cough suppression during general anesthetic emergence as regard number and severity.

Enrollment: 300 estimated patients

Sex: All

Ages: 21 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Aged 21-60 years.
• Both genders.
• Body mass index < 30 kg/ m2
• American Society of Anesthesiology (ASA) physical status I-II.
• Mallampati score class I or II.
• Patients undergoing surgery under general anesthesia.

Exclusion criteria

• Known allergy to study drugs.
• History of psychiatric illness.
• Patients with major organ diseases.
• Pre-existing neurological deficits.
• Body mass index >30 kg/m2.
• Active airway infection or history of tracheal and laryngeal surgery.
• Lower esophageal sphincter incompetence (and reflux).
• Increased intracranial and intraocular pressure.
• Use of cough-inducing medications
• Pregnant, and lactating women.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

300 participants in 4 patient groups, including a placebo group

Dexmedetomidine group ( D group )

Active Comparator group

Description:

Patients will receive 0.5 μg/kg dexmedetomidine in 10 ml normal saline 10 min before the end of surgery.

Treatment:

Drug: Dexmedetomidine

Magnesium sulfate group ( M group )

Active Comparator group

Description:

Patients will receive 30 mg/kg IV magnesium sulfate 50% in 10 ml normal saline 10 min before the end of surgery.

Treatment:

Drug: Magnesium sulfate

Lidocaine group ( L group )

Active Comparator group

Description:

Patients will receive lidocaine 1.5 mg/kg lidocaine in 10 ml normal saline 10 min before the end of surgery.

Treatment:

Drug: Lidocaine

Control group ( C group )

Placebo Comparator group

Description:

Patients will receive 10 ml normal saline 10 min before the end of surgery.

Treatment:

Drug: normal saline